Warfarin

Warfarin, sold under the brand name Coumadin among others, is used as an anticoagulant medication.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 8 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Warfarin, sold under the brand name Coumadin among others, is used as an anticoagulant medication. It is commonly used to prevent deep vein thrombosis and pulmonary embolism, and to protect against stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves.

Warfarin may sometimes be prescribed following a ST-segment elevation myocardial infarction and orthopedic surgery. It is usually taken by mouth, but may also be administered intravenously. The common side effect, a natural consequence of reduced clotting, is bleeding.

Less common side effects may include areas of tissue damage, and purple toes syndrome. Use is not recommended during pregnancy. The effects of warfarin are typically monitored by checking prothrombin time (INR) every one to four weeks.

Many other medications and dietary factors can interact with warfarin, either increasing or decreasing its effectiveness. The effects of warfarin may be reversed with phytomenadione (vitamin K 1 ), fresh frozen plasma, or prothrombin complex concentrate. Warfarin decreases blood clotting by blocking vitamin K epoxide reductase, an enzyme that reactivates vitamin K 1 .

Without sufficient active vitamin K 1 , the plasma concentrations of clotting factors II, VII, IX, and X are reduced and thus have decreased clotting ability.…

Warfarin, sold under the brand name Coumadin among others, is used as an anticoagulant medication. It is commonly used to prevent deep vein thrombosis and pulmonary embolism, and to protect against stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves.

Warfarin may sometimes be prescribed following a ST-segment elevation myocardial infarction and orthopedic surgery. It is usually taken by mouth, but may also be administered intravenously. The common side effect, a natural consequence of reduced clotting, is bleeding.

Less common side effects may include areas of tissue damage, and purple toes syndrome. Use is not recommended during pregnancy. The effects of warfarin are typically monitored by checking prothrombin time (INR) every one to four weeks.

Many other medications and dietary factors can interact with warfarin, either increasing or decreasing its effectiveness. The effects of warfarin may be reversed with phytomenadione (vitamin K 1 ), fresh frozen plasma, or prothrombin complex concentrate. Warfarin decreases blood clotting by blocking vitamin K epoxide reductase, an enzyme that reactivates vitamin K 1 .

Without sufficient active vitamin K 1 , the plasma concentrations of clotting factors II, VII, IX, and X are reduced and thus have decreased clotting ability. The anticlotting protein C and protein S are also inhibited, but to a lesser degree. It is wrongly described as a "vitamin K antagonist".

This term is incorrect. Warfarin does not antagonize the action of vitamin K1, but rather antagonizes vitamin K1 recycling, depleting active vitamin K1. A few days are required for full effect to occur, and these effects can last for up to five days.

Because the mechanism involves enzymes such as VKORC1, patients on warfarin with polymorphisms of the enzymes may require adjustments in therapy if the genetic variant that they have is more readily inhibited by warfarin, thus requiring lower doses. Warfarin first came into large-scale commercial use in 1948 as a rat poison.

It was formally approved as a medication to treat blood clots in humans by the U.S. Food and Drug Administration in 1954. In 1955, warfarin's reputation as a safe and acceptable treatment for coronary artery disease, arterial plaques, and ischemic strokes was bolstered when President Dwight D. Eisenhower was treated with warfarin following a highly publicized heart attack.

It is on the World Health Organization's List of Essential Medicines. Warfarin is available as a generic medication and is sold under many brand names. In 2023, it was the 116th most commonly prescribed medication in the United States, with more than 5 million prescriptions.

Overdose

The major side effect of warfarin use is bleeding. Risk of bleeding is increased if the INR is out of range (due to accidental or deliberate overdose or due to interactions). Many drug interactions can increase the effect of warfarin, also causing an overdose.

In patients with supratherapeutic INR but INR less than 10 and no bleeding, it is enough to lower the dose or omit a dose, monitor the INR and resume warfarin at an adjusted lower dose when the target INR is reached. For people who need rapid reversal of warfarin – such as due to serious bleeding – or who need emergency surgery, the effects of warfarin can be reversed with vitamin K, prothrombin complex concentrate (PCC), or fresh frozen plasma (FFP).

Generally, four-factor PCC can be given more quickly than FFP, the amount needed is a smaller volume of fluid than FFP, and does not require ABO blood typing. Administration of PCCs results in rapid hemostasis, similar to that of FFP, namely, with comparable rates of thromboembolic events, but with reduced rates of volume overload.

Blood products should not be routinely used to reverse warfarin overdose, when vitamin K could work alone. While PCC has been found in lab tests to be better than FFP, when rapid reversal is needed, as of 2018, whether a difference in outcomes such as death or disability exists is unclear.

When warfarin is being given and INR is in therapeutic range, simple discontinuation of the drug for five days is usually enough to reverse the effect and cause INR to drop below 1.5.

Occupational safety

Warfarin used for pest control is a hazardous substance harmful to health. People can be exposed to warfarin in the workplace by breathing it in, swallowing it, skin absorption, and eye contact. The Occupational Safety and Health Administration has set the legal limit (permissible exposure limit) for warfarin exposure in the workplace as 0.1 mg/m 3 over an 8-hour workday.

The National Institute for Occupational Safety and Health has set a recommended exposure limit of 0.1 mg/m 3 over an 8-hour workday. At levels of 100 mg/m 3 , warfarin is immediately dangerous to life and health.

It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U.S. Emergency Planning and Community Right-to-Know Act (42 U.S.C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.

Rodents

River in Steendorp, Belgium: The tube contains bromadiolone, a second-generation ("super-warfarin") anticoagulant. Coumarins (4-hydroxycoumarin derivatives) are used as rodenticides for controlling rats and mice in residential, industrial, and agricultural areas.

Warfarin is both odorless and tasteless, and is effective when mixed with food bait, because the rodents will return to the bait and continue to feed over a period of days until a lethal dose is accumulated (considered to be 1 mg/kg/day over about six days). It may also be mixed with talc and used as a tracking powder, which accumulates on the animal's skin and fur, and is subsequently consumed during grooming.

The for warfarin is 50–100 mg/kg for a single dose, after 5–7 days. 1 mg/kg for repeated daily doses for 5 days, after 5–8 days. The IDLH value is 100 mg/m 3 (warfarin; various species).

Resistance to warfarin as a poison has developed in many rat populations due to an autosomal dominant on chromosome 1 in brown rats. This has arisen independently and become fixed several times around the world.

Other 4-hydroxycoumarins used as rodenticides include coumatetralyl and brodifacoum, which is sometimes referred to as "super-warfarin", because it is more potent, longer-acting, and effective even in rat and mouse populations that are resistant to warfarin. Unlike warfarin, which is readily excreted, newer anticoagulant poisons also accumulate in the liver and kidneys after ingestion.

However, such rodenticides may also accumulate in birds of prey and other animals that eat the poisoned rodents or baits.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368670593 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

21 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.